Traditional MedicareCoverageMedium impact
Tumor Antigen by Immunoassay - CA 19-9
Medicare/CMS - NCD·Oncology, Gastroenterology, Internal Medicine +1 more·National Coverage Determination
We identified it
Oct 2, 2026
Summary
This is a National Coverage Determination (NCD 190.30) for CA 19-9 tumor antigen testing by immunoassay. Without access to the full policy details beyond the title and metadata, the specific coverage criteria, limitations, or changes cannot be determined. The billing team must review the complete policy at the CMS source URL to identify any changes from previous guidance.
Action Required
By October 8, 2026: Billing team must access and review the full National Coverage Determination 190.30 at https://www.cms.gov/medicare-coverage-database/data/ncd?ncdid=142&ncdver=1 to identify specific changes from the previous version. Document any changes to coverage criteria, medical necessity requirements, or billing restrictions for CA 19-9 immunoassay testing. Update billing software, prior authorization protocols, and provider documentation requirements as needed based on the complete policy text. Identify the appropriate CPT or HCPCS code(s) for CA 19-9 testing and ensure compliance with any new or modified coverage conditions. Failure to align with the updated NCD may result in claim denials for Medicare beneficiaries.